Ekso Bionics Announces Appointment of Christian Babini as Vice President of Sales, Americas
RICHMOND, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (“Ekso”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Christian Babini has been appointed to the role of Vice President of Sales, Americas.
“We are thrilled to welcome Christian to the Ekso team,” commented Thomas Looby, Ekso’s President and Chief Executive Officer. “He has built an impressive track record of delivering outstanding results throughout his career, and we are confident that his diverse and extensive experience will be an invaluable asset as we ramp up our sales infrastructure and work toward achieving our vision of improving the lives of patients while creating value for our shareholders.”
Mr. Babini added, “I am excited to join Ekso Bionics, a leader in the field of robotic technology, and lead the Americas sales team. Ekso’s innovative exoskeleton portfolio provides significant value to our customers, and I look forward to helping accelerate our sales effort and expand our market presence.”
Mr. Babini brings more than 20 years of diverse medical device sales experience to Ekso. Most recently, he served as Global Vice President, Sales and Market Development at Medtech Surgical from 2014 until its acquisition by Zimmer Biomet in 2016. Prior to that, he served as Regional Vice President of Sales at Intuitive Surgical, Inc., where he contributed to a substantial acceleration of robotic adoption and helped develop the sales training program during his 10 years with the company. He previously served in various sales leadership roles at U.S. Surgical Corp. Mr. Babini earned a Bachelor of Science in Communications from Eastern Michigan University.
About Ekso Bionics
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Carrie Yamond 917-371-2320 firstname.lastname@example.org Investor Contact: Matthew Ventimiglia 212-599-1265 email@example.com
Released August 30, 2017